Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be

The video discusses biotech companies, focusing on those without products in the market and their volatility. It compares different ETFs, highlighting their holdings and market performance. The discussion includes the impact of market dynamics, takeovers, and the role of large-cap companies like Gilead and Moderna. The video also explores the concept of a biothreat ETF, its potential, and the challenges faced in bringing it to market.

What is a characteristic of biotech companies with no products in the market?

• They have stable stock prices.

• They are often large-cap companies.

• They are involved in clinical trials.

• They have a low acquisition rate.

Which company was mentioned as being acquired by Gilead?

• Clorox

• Regeneron

• Company 47

• Moderna

What is a key difference between BBC and BBP ETFs?

• BBP targets companies farther along in the process.

• BBC has a higher market cap than BBP.

• BBP targets companies with no products in the market.

• BBC focuses on companies with products in the market.

Why did the 'Germ' ETF not make it to market initially?

• It was not approved by regulators.

• The issuer lacked size and scale.

• It was not a viable investment theme.

• Lack of interest from investors.

What type of companies does the 'Germ' ETF focus on?

• Only small-cap companies.

• Only large-cap companies.

• Companies involved in biological threats.

• Companies with stable stock prices.